CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -4.50% for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -4.50%, a 186.54% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 5.20%, a 550.00% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.80%, a 11.11% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 0.90%, a 25.00% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-27 | -4.50% 10-K · filed 2026-02-18 |
| 2024-12-28 | 5.20% 10-K · filed 2025-02-19 |
| 2023-12-30 | 0.80% 10-K · filed 2025-02-19 |
| 2022-12-31 | 0.90% 10-K · filed 2025-02-19 |
| 2021-12-25 | 1.20% 10-K · filed 2024-02-14 |
| 2020-12-26 | 1.00% 10-K · filed 2023-02-22 |
| 2019-12-28 | 1.70% 10-K · filed 2022-02-16 |
| 2018-12-29 | 1.00% 10-K · filed 2021-02-17 |
| 2017-12-30 | 1.30% 10-K · filed 2020-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |